All In Biotech

Drug Trial Radar · NCT01658124

Haemorrhage Alleviation With Tranexamic Acid- Intestinal System

Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,009 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,009

Actual

Start

Jul 2013

Primary completion

Jul 19, 2019

Study completion Jul 19, 2019

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rawalpindi Medical College; University of Ibadan
First posted
Aug 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Severe bleeding in the digestive system is a common symptom of many diseases. Each year, about 50,000 people end up in British hospitals because of this problem and about 5,000 of them die. The most common cause of this bleeding is stomach ulcers. In sub-Saharan Africa, schistosomiasis (parasitic worms) is responsible for about 130,000 deaths from stomach bleeding each year. From previous research in other bleeding conditions such as surgery and trauma, we know that a drug called tranexamic acid can reduce bleeding and save lives. We now want to do the HALT-IT trial to see if giving tranexamic acid can save lives and if there are any complications in people with severe bleeding from the digestive system.

Conditions

  • Gastrointestinal Bleeding

Interventions

  • Tranexamic AcidDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome is death from haemorrhageTime frame: within 5 days of randomisation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Over 50 countries Worldwide

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.